{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:21:03Z","timestamp":1787757663340,"version":"build-2784847793"},"reference-count":51,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    An international panel of experts from the U.S. and China convened to discuss the\n                    <jats:italic>2026<\/jats:italic>\n                    <jats:italic>TOS\u2013OMA\u2013OAC Expert Guidance Statement on the Pharmacological Management of Obesity,<\/jats:italic>\n                    focusing on emerging evidence, regional considerations, and challenges in translating recommendations into long\u2010term care. Panelists reached a consensus that obesity should be recognized as a chronic and progressive disease, for which pharmacotherapy is lifelong once initiated, as discontinuation consistently leads to weight regain and loss of metabolic benefit. The discussion highlighted a shift toward treating obesity itself as an upstream intervention capable of modifying multiple obesity\u2010related complications, with greater weight loss generally conferring greater clinical benefit. Visceral adipose tissue emerged as a particularly relevant therapeutic target, especially in Asian populations, where substantial metabolic risk may be present at lower BMI levels. Panelists noted heterogeneity in treatment response and that eventual weight\u2010loss plateaus should be anticipated as evidence of maximal effectiveness rather than medication failure. The panel endorsed an individualized, stepwise approach integrating pharmacotherapy and metabolic surgery as complementary strategies. Finally, the panel emphasized that translating therapeutic advances into real\u2010world benefit will require addressing practical barriers related to policy, access, affordability, and stigma to ensure effective care reaches those who need it most.\n                  <\/jats:p>","DOI":"10.1002\/oby.70263","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:48:08Z","timestamp":1787755688000},"page":"1708-1717","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Guidelines to Clinical Practice: Expert Perspectives on Long\u2010Term Management of Obesity"],"prefix":"10.1002","volume":"34","author":[{"given":"Hong","family":"Chen","sequence":"first","affiliation":[{"name":"Zhujiang Hospital of Southern Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Zhongda Hospital, Southeast University  Nanjing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaihong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine The Third Xiangya Hospital of Central South University  Changsha China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc\u2010Andr\u00e9","family":"Cornier","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes &amp; Metabolic Diseases, Department of Medicine Medical University of South Carolina  Charleston South Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Q","family":"Purnell","sequence":"additional","affiliation":[{"name":"Department of Medicine Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"5","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the Use and Indications of Glucagon\u2010Like Peptide\u20101 Therapies for the Treatment of Obesity in Adults","volume":"335","author":"Celletti F.","year":"2026","journal-title":"JAMA"},{"key":"e_1_2_8_3_1","unstructured":"Institute for Health Metrics and Evaluation \u201cThe Lancet: More Than Half of Adults and a Third of Children and Adolescents Predicted to Have Overweight or Obesity by 2050 \u201dpublished March 3 2025 https:\/\/www.healthdata.org\/news\u2010events\/newsroom\/news\u2010releases\/lancet\u2010more\u2010half\u2010adults\u2010and\u2010third\u2010children\u2010and\u2010adolescents."},{"issue":"1","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1186\/s12889-025-23237-7","article-title":"Global, Regional, and National Burden of Mortality and DALYs Attributable to High Body Mass Index From 1990 to 2021 With Projections to 2036","volume":"25","author":"Xie F.","year":"2025","journal-title":"BMC Public Health"},{"key":"e_1_2_8_5_1","volume-title":"StatPearls","author":"Daley S. F.","year":"2025"},{"issue":"23","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long\u2010Term Pharmacotherapy in the Management of Obesity: National Task Force on the Prevention and Treatment of Obesity","volume":"276","year":"1996","journal-title":"JAMA"},{"issue":"8","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17081036","article-title":"Emerging Frontiers in GLP\u20101 Therapeutics: A Comprehensive Evidence Base","volume":"17","author":"Patel S.","year":"2025","journal-title":"Pharmaceutics"},{"issue":"3","key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11154-013-9252-x","article-title":"Metabolically Healthy Obesity: Definitions, Determinants and Clinical Implications","volume":"14","author":"Phillips C. M.","year":"2013","journal-title":"Reviews in Endocrine & Metabolic Disorders"},{"issue":"2","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S2213-8587(13)70062-7","article-title":"Metabolically Healthy Obesity: Epidemiology, Mechanisms, and Clinical Implications","volume":"1","author":"Stefan N.","year":"2013","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"e_1_2_8_10_1","unstructured":"A.Saha \u201cSemaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity\u2014SELECT \u201dlast modified September 12 2024 https:\/\/www.acc.org\/Latest\u2010in\u2010Cardiology\/Clinical\u2010Trials\/2023\/11\/09\/15\/04\/select."},{"issue":"21","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2010Associated Steatohepatitis","volume":"392","author":"Sanyal A. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2010Associated Steatohepatitis With Liver Fibrosis","volume":"391","author":"Loomba R.","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A New Framework for the Diagnosis, Staging and Management of Obesity in Adults","volume":"30","author":"Busetto L.","year":"2024","journal-title":"Nature Medicine"},{"issue":"2","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Apovian C. M.","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1037\/0003-066X.62.3.220","article-title":"Medicare's Search for Effective Obesity Treatments: Diets Are Not the Answer","volume":"62","author":"Mann T.","year":"2007","journal-title":"American Psychologist"},{"issue":"4","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.gtc.2023.08.001","article-title":"Lifestyle\u2010Based Obesity Care","volume":"52","author":"Ryan D. H.","year":"2023","journal-title":"Gastroenterology Clinics of North America"},{"issue":"4","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s13679-020-00416-8","article-title":"Developing Integrated Clinical Pathways for the Management of Clinically Severe Adult Obesity: A Critique of NHS England Policy","volume":"9","author":"Hazlehurst J. M.","year":"2020","journal-title":"Current Obesity Reports"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/oby.70164","article-title":"Joint TOS\/OMA\/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach","volume":"34","author":"Alexander L.","year":"2026","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"90","article-title":"Chinese Guidelines for the Clinical Management of Obesity (2024 Edition)","volume":"16","author":"Department of Medical Administration, National Health Commission of the People's Republic of China","year":"2025","journal-title":"Medical Journal of Peking Union Medical College Hospital"},{"key":"e_1_2_8_20_1","unstructured":"Obesity Canada \u201cAdult Obesity Pharmacotherapy Decision Tool (Portrait) \u201dhttps:\/\/obesitycanada.ca\/wp\u2010content\/uploads\/2025\/08\/2025\u2010Obesity\u2010Pharmacotherapy\u2010Decision\u2010Tool\u2010Table\u2010portrait.pdf."},{"issue":"10","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1038\/s41591-025-03765-w","article-title":"Framework for the Pharmacological Treatment of Obesity and Its Complications From the European Association for the Study of Obesity (EASO)","volume":"31","author":"McGowan B.","year":"2025","journal-title":"Nature Medicine"},{"issue":"1","key":"e_1_2_8_22_1","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbaf018","article-title":"Trends of Obesity Management in Adults: An Analysis Across Guidelines in China and in Europe","volume":"8","author":"Qu S.","year":"2025","journal-title":"Precision Clinical Medicine"},{"issue":"17","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long\u2010Term Persistence of Hormonal Adaptations to Weight Loss","volume":"365","author":"Sumithran P.","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/oby.21538","article-title":"Persistent Metabolic Adaptation 6\u2009Years After \u2018The Biggest Loser\u2019 Competition","volume":"24","author":"Fothergill E.","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177850","article-title":"Recent Progress in the Pharmacotherapy for Obesity","volume":"1002","author":"Lu J.","year":"2025","journal-title":"European Journal of Pharmacology"},{"issue":"9","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of Liraglutide on Visceral and Ectopic Fat in Adults With Overweight and Obesity at High Cardiovascular Risk: A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Clinical Trial","volume":"9","author":"Neeland I. J.","year":"2021","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"11","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15377","article-title":"Adipose Tissue Dysfunction and Visceral Fat Are Associated With Hepatic Insulin Resistance and Severity of NASH Even in Lean Individuals","volume":"42","author":"Saponaro C.","year":"2022","journal-title":"Liver International"},{"issue":"1","key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"21388","DOI":"10.1038\/s41598-024-72246-w","article-title":"Impact of Diet Intervention on Visceral Adipose Tissue and Hepatic Fat in Patients With Obesity or Type 2 Diabetes: A Randomized Trial","volume":"14","author":"Krittayaphong R.","year":"2024","journal-title":"Scientific Reports"},{"issue":"15","key":"e_1_2_8_29_1","first-page":"S271","article-title":"Increasing Clinical Awareness of Obesity as a Serious, Chronic, Relapsing, and Treatable Disease","volume":"28","author":"Lazarus E.","year":"2022","journal-title":"American Journal of Managed Care"},{"issue":"2","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT\u20104 Trial","volume":"186","author":"Horn D. B.","year":"2026","journal-title":"JAMA Internal Medicine"},{"key":"e_1_2_8_31_1","unstructured":"A. Studna; Applied Clinical Trials \u201cFDA Approves Oral Wegovy Following Positive Phase 3 OASIS 4 Trial Results \u201d published December 23 2025 https:\/\/www.appliedclinicaltrialsonline.com\/view\/fda\u2010approves\u2010oral\u2010wegovy\u2010positive\u2010oasis\u2010trial\u2010results."},{"key":"e_1_2_8_32_1","unstructured":"Eli Lilly and Company \u201cFDA Approves Lilly's Foundayo (Orforglipron) the Only GLP\u20101 Pill for the Treatment of Adults With Obesity or Overweight \u201dpublished April 1 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/fda\u2010approves\u2010lillys\u2010foundayotm\u2010orforglipron\u2010only\u2010glp\u20101\u2010pill."},{"key":"e_1_2_8_33_1","unstructured":"A. K.Allen \u201cEli Lilly's Oral GLP\u20101RA Maintains Weight Loss from Injectable Drugs \u201dClinical Trials Arena published December 19 2025 https:\/\/www.clinicaltrialsarena.com\/news\/eli\u2010lilly\u2010orforglipron\u2010phase\u2010iii\u2010obesity\u2010weight\u2010maintenance\u2010trial\/."},{"issue":"12","key":"e_1_2_8_34_1","article-title":"Assessment of Noninferiority of Oral vs Subcutaneous Semaglutide: A Systematic Review and Meta\u2010Analysis","volume":"135","author":"Drygalski K.","year":"2025","journal-title":"Polish Archives of Internal Medicine"},{"issue":"9403","key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate Body\u2010Mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"issue":"10516","key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and Cardiovascular Outcomes by Baseline and Changes in Adiposity Measurements: A Prespecified Analysis of the SELECT Trial","volume":"406","author":"Deanfield J.","year":"2025","journal-title":"Lancet"},{"issue":"21","key":"e_1_2_8_37_1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111540","article-title":"Systemic Inflammation Across Metabolic Obesity Phenotypes: A Cross\u2010Sectional Study of Korean Adults Using High\u2010Sensitivity C\u2010Reactive Protein as a Biomarker","volume":"25","author":"Baek S. U.","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of Tirzepatide Versus Insulin Degludec on Liver Fat Content and Abdominal Adipose Tissue in People With Type 2 Diabetes (SURPASS\u20103 MRI): A Substudy of the Randomised, Open\u2010Label, Parallel\u2010Group, Phase 3 SURPASS\u20103 Trial","volume":"10","author":"Gastaldelli A.","year":"2022","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"6","key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and Muscle Composition Changes in People With Type 2 Diabetes (SURPASS\u20103 MRI): A Post Hoc Analysis of a Randomised, Open\u2010Label, Parallel\u2010Group, Phase 3 Trial","volume":"13","author":"Sattar N.","year":"2025","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"7","key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT\u2010CN Randomized Clinical Trial","volume":"332","author":"Zhao L.","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and Safety of Once\u2010Weekly Tirzepatide in Japanese Patients With Obesity Disease (SURMOUNT\u2010J): A Multicentre, Randomised, Double\u2010Blind, Placebo\u2010Controlled Phase 3 Trial","volume":"13","author":"Kadowaki T.","year":"2025","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"3","key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide Once a Week in Adults With Overweight or Obesity, With or Without Type 2 Diabetes in an East Asian Population (STEP 6): A Randomised, Double\u2010Blind, Double\u2010Dummy, Placebo\u2010Controlled, Phase 3a Trial","volume":"10","author":"Kadowaki T.","year":"2022","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"3","key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and Safety of Once Weekly Semaglutide 2.4 mg for Weight Management in a Predominantly East Asian Population With Overweight or Obesity (STEP 7): A Double\u2010Blind, Multicentre, Randomised Controlled Trial","volume":"12","author":"Mu Y.","year":"2024","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"10","key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S2213-8587(25)00164-0","article-title":"Once\u2010Weekly Semaglutide 2.4 mg in an Asian Population With Obesity, Defined as BMI \u226525 kg\/m2 in South Korea and Thailand (STEP 11): A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Phase 3 Trial","volume":"13","author":"Lim S.","year":"2025","journal-title":"Lancet Diabetes and Endocrinology"},{"issue":"22","key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once\u2010Weekly Mazdutide in Chinese Adults With Obesity or Overweight","volume":"392","author":"Ji L.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, Criteria, and Core Concepts of Guidelines for the Management of Obesity Disease in Japan","volume":"71","author":"Ogawa W.","year":"2024","journal-title":"Endocrine Journal"},{"key":"e_1_2_8_47_1","unstructured":"National Health Commission of the People's Republic of China \u201cNotice on Issuing the Implementation Plan for the \u2018Weight Management Year\u2019 Initiative \u201dpublished June 26 2024 https:\/\/www.nhc.gov.cn\/ylyjs\/gzdt\/202406\/41c64b9fd9774352af22f5274c1e831d.shtml."},{"issue":"10","key":"e_1_2_8_48_1","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.2337\/dc20-3097","article-title":"Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC)","volume":"44","author":"Lachin J. M.","year":"2021","journal-title":"Diabetes Care"},{"issue":"13","key":"e_1_2_8_49_1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity","volume":"391","author":"Malhotra A.","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular Outcomes With Tirzepatide Versus Dulaglutide in Type 2 Diabetes","volume":"393","author":"Nicholls S. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_8_51_1","unstructured":"PR Newswire \u201cLilly's Triple Agonist Retatrutide Delivered Weight Loss of Up to an Average of 71.2\u2009lbs Along With Substantial Relief From Osteoarthritis Pain in First Successful Phase 3 Trial \u201dpublished December 11 2025 https:\/\/www.prnewswire.com\/news\u2010releases\/lillys\u2010triple\u2010agonist\u2010retatrutide\u2010delivered\u2010weight\u2010loss\u2010of\u2010up\u2010to\u2010an\u2010average\u2010of\u201071\u20102\u2010lbs\u2010along\u2010with\u2010substantial\u2010relief\u2010from\u2010osteoarthritis\u2010pain\u2010in\u2010first\u2010successful\u2010phase\u20103\u2010trial\u2010302638804.html."},{"issue":"10","key":"e_1_2_8_52_1","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Jastreboff A. M.","year":"2025","journal-title":"New England Journal of Medicine"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:48:39Z","timestamp":1787755719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/oby.70263"],"URL":"https:\/\/doi.org\/10.1002\/oby.70263","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"2026-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}